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Although currently recommended antibiotics for Lyme disease such as doxycycline
or amoxicillin cure the majority of the patients, about 10–20% of patients treated
for Lyme disease may experience lingering symptoms including fatigue, pain, or
joint and muscle aches. Under experimental stress conditions such as starvation
or antibiotic exposure, Borrelia burgdorferi can develop round body forms, which
are a type of persister bacteria that appear resistant in vitro to customary first-line
antibiotics for Lyme disease. To identify more effective drugs with activity against the
round body form of B. burgdorferi, we established a round body persister model
induced by exposure to amoxicillin (50 µg/ml) and then screened the Food and
Drug Administration drug library consisting of 1581 drug compounds and also 22
drug combinations using the SYBR Green I/propidium iodide viability assay. We
identified 23 drug candidates that have higher activity against the round bodies of
B. burgdorferi than either amoxicillin or doxycycline. Eleven individual drugs scored
better than metronidazole and tinidazole which have been previously described to
be active against round bodies. In this amoxicillin-induced round body model, some
drug candidates such as daptomycin and clofazimine also displayed enhanced activity
which was similar to a previous screen against stationary phase B. burgdorferi
persisters not exposure to amoxicillin. Additional candidate drugs active against
round bodies identified include artemisinin, ciprofloxacin, nifuroxime, fosfomycin,
chlortetracycline, sulfacetamide, sulfamethoxypyridazine and sulfathiozole. Two triple
drug combinations had the highest activity against amoxicillin-induced round bodies
and stationary phase B. burgdorferi persisters: artemisinin/cefoperazone/doxycycline
and sulfachlorpyridazine/daptomycin/doxycycline. These findings confirm and extend
previous findings that certain drug combinations have superior activity against
B. burgdorferi persisters in vitro, even when pre-treated with amoxicillin. These findings
may have implications for improved treatment of Lyme disease.
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INTRODUCTION
Lyme disease may affect multiple organs in disseminated
infection and is the most common vector-borne infection
reported in the United States and Europe. In the United States,
the number of reported Lyme disease cases has increased over
last 15 years and a recent calculation estimated that about
300,000 cases occur annually (CDC, 2015a). About 10–20% of
patients treated for Lyme disease with a recommended 2–4 week
antibiotic therapy have lingering symptoms of fatigue, pain, or
joint and muscle aches (CDC, 2015a). In some cases, when
such symptoms extend beyond 6 months after initial antibiotic
treatment, post-treatment Lyme disease syndrome (PTLDS)
has been proposed (CDC, 2015b) that in placebo-controlled,
randomized trials that does not appear to respond to additional
treatment with current Lyme antibiotics (Wormser et al., 2006;
Klempner et al., 2013; Berende et al., 2016), though improved
symptoms were noted in other trials (Krupp et al., 2003; Fallon
et al., 2008).
The spirochete Borrelia burgdorferi sensu lato is the causative
agent of Lyme disease (Meek et al., 1996). B. burgdorferi
is transmitted by tick vectors that also feed upon host
reservoirs including rodents, reptiles, birds and deer (Radolf
et al., 2012). In bacterial culture systems, the morphology
of B. burgdorferi is mainly in spirochetal form during log
phase growth, but transforms to morphological variant forms
such as round bodies and microcolonies in older, stationary
phase cultures (Feng et al., 2014a, 2015) or when the bacteria
are subjected to adverse or stress conditions (Brorson and
Brorson, 1997; Murgia and Cinco, 2004). For example, oxidative
stress, pH variation, heat and antibiotic exposure can induce
B. burgdorferi to form round bodies (sometimes referred to
as cystic forms which are coccoid and membrane-bound cells)
(Kersten et al., 1995; Murgia and Cinco, 2004; Brorson et al.,
2009).
In vitro studies have shown that the round body form
of B. burgdorferi is not only viable but also could revert
to spirochetal form under suitable conditions (Brorson and
Brorson, 1997; Murgia and Cinco, 2004). These round bodies
appear to have both lower metabolism and greater resistance
to antibiotic treatment, which appears common to stationary
phase bacteria in culture generally. Some have suggested that
these round body forms might be a protective mechanism to
overcome adverse environmental conditions (Murgia and Cinco,
2004; Brorson et al., 2009). Although the round body forms
of B. burgdorferi have been described in human infections
including brain tissue (Miklossy et al., 2008), this finding
has not been widely observed in the scientific literature, and
their significance in Lyme disease is unclear (Lantos et al.,
2014).
Amoxicillin and doxycycline are among the most commonly
used frontline drugs for the treatment of Lyme disease, but
have poor activity against in vitro, stationary phase cultures
enriched with persister forms including round bodies and
microcolonies (Kersten et al., 1995; Brorson et al., 2009; Barthold
et al., 2010; Sapi et al., 2011; Feng et al., 2015). Commonly
used Lyme antibiotics doxycycline and penicillin have been
shown experimentally to induce B. burgdorferi from spirochetal
to round bodies or cystic round structures forms in culture
(Kersten et al., 1995). In this study, we took advantage of
this observation and established a round body persister model
using amoxicillin-treated organisms to screen a FDA-approved
drug library with a newly developed SYBR Green I/propidium
iodide (PI) assay (Feng et al., 2014a,b). We sought to investigate
whether some non-traditional drugs or drug combinations had
improved activity against the amoxicillin-induced round body
form as distinct from the previous drug candidates identified
from non-antibiotic treated stationary phase culture (Feng et al.,
2014a).
MATERIALS AND METHODS
Strain, Media and Culture
Borrelia burgdorferi strain B31 was obtained from American Type
Tissue Collection. B. burgdorferi and was cultured in BSK-H
media (HiMedia Laboratories Pvt. Ltd.), with 6% rabbit serum
(Sigma–Aldrich, Co). All culture media were filter-sterilized by
0.2 µm filter. Cultures were incubated in sterile 50 mL closed
conical tubes (BD Biosciences, San Jose, CA, USA) at 33◦C
without antibiotics.
Induction of Round Body Form of
B. burgdorferi
For induction of B. burgdorferi to round body forms,
B. burgdorferi spirochetes (1 × 105 spirochetes/ml) were
cultured in BKS-H medium for 5 days without shaking when
the bacteria are still in log phase (Feng et al., 2014a). After
5 days of incubation, amoxicillin at a final concentration
of 50 µg/ml was added to the culture for round body form
induction. After 72 h at 33◦C, B. burgdorferi were examined
by microscopy following SYBR Green I/PI staining to confirm
round body formation. The round body cells (100 µl) were
transferred to 96-well tissue culture microplates for evaluation
of the effects of treatment with antibiotics or FDA drug
library (see below). To confirm the viability of induced round
body form, we subcultured the induced round bodies in
fresh BSK-H medium. The round bodies (in 500 µl culture)
were collected by centrifugation and rinsed with 1 ml fresh
BSK-H medium followed by resuspension in 500 µl fresh
BSK-H medium. Then 50 µl of cell suspension was transferred
to 1 ml fresh BSK-H medium for subculture at 33◦C for
5 days.
Microscopy Techniques
Specimens were examined on a Nikon Eclipse E800 microscope
equipped with differential interference contrast (DIC) and epi-
fluorescence illumination, and recorded with a Spot slider color
camera. Cell proliferation assays were performed by direct
counting using a bacterial counting chamber (Hausser Scientific
Partnership, Horsham, PA, USA) and DIC microscopy. To assay
the viability of B. burgdorferi, the SYBR Green I/PI assay (Feng
et al., 2014a) was performed. The ratio of live (green) and dead
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(red) B. burgdorferi was calculated by counting the cells using a
bacterial counting chamber and epi-fluorescence microscopy.
Antibiotics and FDA Drug Library
Doxycycline, metronidazole, cefmetazole, rolitetracycline,
sulfachlorpyridazine, artemisinin, cefoperazone, daptomycin
(Sigma–Aldrich) were dissolved in suitable solvents (Wikler and
Ferraro, 2008) to form stock solutions. The antibiotic stocks
were filter-sterilized by 0.2 µm filter, except metronidazole and
artemisinin which were dissolved in dimethylsulfoxide (DMSO)
and not filtered. Then the stocks were diluted into 500 µM
pre-diluted stocks and stored at−20◦C.
Each drug in the JHCCL FDA-approved drug library version
1.32 (Chong et al., 2006) was predispensed in 10 mM stock
solutions with DMSO. The stock solutions were arrayed in a total
of 27 96-well plates, leaving the first and the last columns in each
plate as controls. Each solution in these master plates was diluted
with PBS to make 500 µM pre-diluted working stock plates. The
first and the last columns in each pre-diluted plate were set as
blank controls, doxycycline control, metronidazole control and
amoxicillin control. The pre-diluted drug stock plates were sealed
and stored at−20◦C.
Drug Screen and Antibiotic Susceptibility
Testing
To qualitatively determine the effect of antibiotics in a high-
throughput manner, 10µl of each compound (final concentration
50 µM) from the pre-diluted plate or pre-diluted stock was
added to 3 days amoxicillin induced round body form from a
5 day-old stationary phase B. burgdorferi culture in the 96-well
plate. The final volume per well was adjusted to 100 µl. Plates
were sealed and placed in 33◦C incubator for 7 days. SYBR
Green I/PI viability assay was used to assess the live and dead
cells after antibiotic exposure as described (Feng et al., 2014a).
Briefly, 10 µl of SYBR Green I (10,000 × stock, Invitrogen)
was mixed with 30 µl propidium iodide (PI, 20 mM, Sigma)
into 1.0 ml of sterile dH2O. Then 10 µl staining mixture
was added to each well and mixed thoroughly. The plates
were incubated at room temperature in the dark for 15 min
followed by plate reading at excitation wavelength at 485 nm
and the fluorescence intensity at 535 nm (green emission) and
635 nm (red emission) in microplate reader (HTS 7000 plus
Bio Assay Reader, PerkinElmer Inc., USA). With least-square
fitting analysis, the regression equation and regression curve of
the relationship between percentage of live and dead bacteria
as shown in green/red fluorescence ratios was obtained. The
regression equation was used to calculate the percentage of live
cells in each well of the 96-well plate.
The standard microdilution method (Chong et al., 2006)
was used to determine the minimum inhibitory concentration
(MIC) that would inhibit visible growth of B. burgdorferi after
72 h incubation. B. burgdorferi cells (1 × 105) were inoculated
into each well of a 96-well microplate containing 90 µL fresh
BSK-H medium per well. Each diluted compound (10 µL) was
added to the culture. All experiments were run in triplicate.
The 96-well plate was sealed and placed in an incubator at
33◦C for 5 days. Cell proliferation was assessed using the SYBR
Green I/PI assay and a bacterial counting chamber after the
incubation.
Subculture of Antibiotic-Treated
B. burgdorferi to Assess Viability of the
Organisms
Amoxicillin-induced round body form and 10-day old stationary
phase culture (500µl) of B. burgdorferi was treated with 10µg/ml
drugs or their combinations for 7 days in 1.5 ml Eppendorf
tubes as described previously (Feng et al., 2015). After incubation
at 33◦C for 7 days without shaking, the cells were collected
by centrifugation and rinsed with 1 ml fresh BSK-H medium
followed by resuspension in 500µl fresh BSK-H medium without
antibiotics. Then 50 µl of cell suspension was transferred to 1 ml
fresh BSK-H medium for subculture at 33◦C for 10–20 days.
Cell proliferation was assessed using SYBR Green I/PI assay
and bacterial counting chamber (Hausser Scientific Partnership,
Horsham, PA, USA) by microscopy as described above.
RESULTS
Induction of Round Body Form of
B. burgdorferi by Amoxicillin
Beta-lactam antibiotics are among the most commonly used
drugs for the treatment of Lyme disease, but intriguingly in vitro
induce spirochetal B. burgdorferi to form round bodies that
are subsequently resistant to many antibiotics (Brorson et al.,
2009; Sapi et al., 2011). In order to identify FDA-library drugs
active against the round body form of B. burgdorferi, we first
assessed conditions that yielded the highest induction of round
body forms. The 6-day or older culture could not be induced
to round body form completely (<80%) with even 100 µg/ml
amoxicillin (Figure 1D), whereas a 5-day B. burgdorferi culture
treated with 50 µg/ml amoxicillin for 72 h was the best condition
for producing round bodies. Microscopic examination showed
that in 5-day old culture after 3-day amoxicillin induction, up to
96% of the B. burgdorferi spirochetes could be induced into round
bodies by amoxicillin (Figure 1A). To confirm that the induced
round body form was still viable, we performed a subculture
test in fresh BSK-H medium. Microscopy analysis revealed that
amoxicillin-induced round bodies of B. burgdorferi could revert
to spirochetes (95 ∼ 99%, n = 5) in BSK-H medium after 5 days
subculture (Figure 1), indicating that the round bodies induced
by amoxicillin treatment remained viable upon subculture.
To compare the antibiotic susceptibility of the round body
form of B. burgdorferi with the spirochetal form, we tested
commonly used antibiotics for Lyme disease including
doxycycline, cefuroxime, and ceftriaxone on 5-day old
spirochetes and amoxicillin-induced round body form of
B. burgdorferi. The results showed that the round body form of
B. burgdorferi was more tolerant or resistant to antibiotics than
the spirochetal form (Figure 2). The amoxicillin induced-round
body form was subsequently used for drug screens as described
below.
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FIGURE 1 | Microscopy demonstrating round body formation in the
presence of amoxicillin and subsequent reversion to spirochetal form
of B. burgdorferi during subculture. (A) A 5-day old B. burgdorferi culture
without amoxicillin consisting primarily of spirochetal form. (B) Coccoid round
body forms formed from B. burgdorferi spirochetes upon treatment with
amoxicillin (50 µg/ml) for 3 days. (C) Reversion of round body form of
B. burgdorferi from (B) to spirochetal form after 5 days subculture in fresh
BSK-medium. (D) 7-day old stationary phase B. burgdorferi treated with
100 µg/ml amoxicillin for 3 days. The images were derived from the above
samples stained by SYBR Green PI viability assay followed by microscopy
(400 × magnification) as described in Section “Materials and Methods.”
Screen for Drugs Active against Round
Bodies of B. burgdorferi
Round body forms of B. burgdorferi are resistant to many
antibiotics (Brorson et al., 2009; Sapi et al., 2011), so we
used 50 µM concentration to increase the sensitivity of
the FDA drug library screen. The amoxicillin-induced round
bodies of B. burgdorferi were incubated in the 96 well plates
with the library drug compounds (50 µM) for 7 days. As
prior studies suggested that metronidazole and tinidazole
were active against the round body form of B. burgdorferi
(Brorson and Brorson, 1999; Sapi et al., 2011), they were
included in each plate as positive controls for comparison
in the drug screen. Of the 1581 FDA-library drugs tested,
23 antibiotics were found to have higher activity against
the round bodies of B. burgdorferi than amoxicillin (46%
residual viable cells) and doxycycline (42% residual viable cells)
(Table 1). These effective hits were confirmed in further rescreens
followed by fluorescence microscope counting after SYBR Green
I/PI stain to verify the screening results. Among the 23
effective hits, 11 drugs (daptomycin, artemisinin, ciprofloxacin,
sulfacetamide, sulfamethoxypyridazine, nifuroxime, fosfomycin,
chlortetracycline, sulfathiazole, clofazimine and cefmenoxime, in
order of decreasing activity) had better activity than compounds
previously described with round body activity: metronidazole
and tinidazole (each with 33% residual viable cells) (Table 1;
Figure 3). The antimalarial drug artemisinin showed higher
activity (24% residual viable cells) against the round bodies
of B. burgdorferi. Interestingly, ciprofloxacin (28% residual
viable cells) was the most active among quinolone drugs
FIGURE 2 | Exposure of spirochetal form and amoxicillin-induced
round bodies of B. burgdorferi (5-day old) to different antibiotics. Log
phase spirochetal form (5 day old) and amoxicillin-induced round bodies of
B. burgdorferi (5-day old) were exposed to 50 µM doxycycline, cefuroxime,
and ceftriaxone, respectively, for 5 days. The percentage of residual live cells
(n = 3) was determined by SYBR Green I/PI assay followed by fluorescence
microscopy counting.
tested compared to levofloxacin 41%, norfloxacin 41%, and
moxifloxacin 49%. In addition, chlortetracycline, meclocycline
and rolitetracycline were more active than doxycycline (42%
residual live cells) against the round bodies (Table 1).
On the other hand, some cell wall inhibitors such as
vancomycin and macrolide antibiotic carbomycin, which had
reasonable activity against stationary phase B. burgdorferi in
our previous study (Feng et al., 2014a) showed relatively
weak activity against the amoxicillin-induced round bodies
of B. burgdorferi with 38 and 43% residual live cells,
respectively.
MIC Values of Round Body Active
Antibiotics
In our previous study, we found that the activity of antibiotics
against non-growing persisters was not always correlated with
their activity against growing B. burgdorferi (Feng et al.,
2014a). We therefore used log phase cultures to test the
MICs of selected active hits artemisinin and ciprofloxacin
that had excellent activity against the round bodies of
B. burgdorferi using the SYBR Green I/PI assay and microscope
counting. The MIC value of artemisinin was quite high at
50∼100 µg/ml for growing B. burgdorferi, indicating that
artemisinin is much less active against growing organisms,
despite its high activity against the non-growing round bodies
of B. burgdorferi persisters. In contrast, ciprofloxacin was
quite active against the growing B. burgdorferi with a low
MIC (0.8∼1.6 µg/ml), which is in agreement with a previous
study (Kraiczy et al., 2001), indicating that it is active against
both growing form and non-growing round body form of
B. burgdorferi.
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TABLE 1 | Twenty-three drugs with better activity than amoxicillin against round bodies of B. burgdorferi∗.
Drugs (50 µM) Cmax (µg/ml)† Residual viable cells‡ Ratios of green/red fluorescence
Primary screening Rescreening Rescreening p-Value§
Amoxicillin 1.5–13.8 46% 6.53 6.59 6.52 1.0000
Doxycycline 3.6–4.6 42% 6.34 6.39 6.67 0.4915
Penicillin G 1.5–2.7 38% 6.33 6.51 6.33 0.0767
Cefuroxime 2.1–13.6 34% 6.29 6.28 6.31 0.0005
Ceftriaxone 200–380 36% 6.37 6.29 6.39 0.0069
Azithromycin 2–5.2 47% 6.79 6.52 6.42 0.8116
Metronidazole 12.5–19.4 33% 6.23 6.30 6.31 0.0014
Tinidazole 40–55 33% 6.24 6.21 6.36 0.0059
Daptomycin¶ 57.8–93.9 19% 5.90 6.09 5.93 0.0008
Artemisinin 0.3–1.6 24% 5.96 6.14 6.17 0.0028
Ciprofloxacin 1.2–5.4 28% 6.30 6.04 6.20 0.0108
Sulfacetamide – 29% 6.26 6.14 6.20 0.0011
Sulfamethoxypyridazine 13.4–22.3 30% 6.20 6.07 6.34 0.0149
Nifuroxime 38.4–65.8 30% 6.10 6.32 6.22 0.0079
Fosfomycin 11.5–12.7 31% 6.39 6.12 6.16 0.0191
Chlortetracycline 4.33 31% 6.20 6.36 6.18 0.0078
Sulfathiazole 132.2 (in hen) 31% 6.38 6.18 6.17 0.0141
Clofazimine 0.47–0.7 32% 6.29 6.22 6.24 0.0008
Cefmenoxime 1.06–1.58 32% 6.18 6.33 6.28 0.0050
Meclocycline 33% 6.52 6.23 6.09 0.1056
Cefmetazole 33% 6.13 6.25 6.46 0.0530
Loracarbef 33% 6.35 6.25 6.24 0.0036
Sisomicin 33% 6.27 6.12 6.45 0.0562
Sulfisoxazole 33% 6.53 6.15 6.18 0.1005
Cefazolin 34% 6.23 6.34 6.29 0.0026
Aztreonam 34% 6.16 6.38 6.33 0.0211
Thymol 34% 6.15 6.36 6.36 0.0257
Cefixime 34% 6.41 6.21 6.27 0.0169
Sulfanilate 34% 6.49 6.03 6.40 0.1649
Ceftazidime 34% 6.20 6.34 6.37 0.0126
Rolitetracycline 35% 6.23 6.35 6.37 0.0085
∗Round body form of B. burgdorferi from 7 day old culture was treated with FDA-library drugs (50 µM) for 7 days. The dark gray shading refers to antibiotics that have
been routinely recommended to treat Lyme disease. Azithromycin is a second line drug. The light gray shading includes drugs previously shown to have activity against
in vitro round bodies (metronidazole, tinidazole) and were used as controls to identify more effective drugs. †Cmax values are derived from the literature. ‡Residual viable
B. burgdorferi was calculated according to the regression equation and ratios of Green/Red fluorescence obtained by SYBR Green I/PI assay. §p-values of standard t-test
were calculated for the select antibiotic treated samples in comparison with the amoxicillin treated sample as a control. ¶Bold type indicates the 11 drug candidates that
had better activity against the round body forms than metronidazole or tinidazole in order of decreasing activity.
Effect of Drug Combinations on the
Round Body Form and the Stationary
Phase B. burgdorferi Persisters
We previously found that stationary phase cultures are enriched
with morphological variants such as round bodies and biofilm-
like aggregated microcolonies (Feng et al., 2014a, 2015). These
morphological variants of B. burgdorferi have different antibiotic
susceptibilities (Brorson et al., 2009; Sapi et al., 2011; Feng
et al., 2015), and our recent study showed that some drug
combinations are more effective against aggregated B. burgdorferi
persisters than single drugs (Feng et al., 2015). To identify
the best drug combinations with the active hits from the
above screens against the round bodies of B. burgdorferi, we
evaluated drugs with improved activity detected in this screening
including artemisinin, cefmetazole, and sulfachlorpyridazine
in combination with drugs identified in the earlier study
that appeared to work well against persisters when used in
combination (Feng et al., 2015). In the drug combination
study, we used 10 µg/ml, a lower concentration near the
achievable Cmax values of most drugs. With this approach,
drug combinations were much more effective than individual
drugs used alone against the round bodies (Table 2; Figure 4).
Overall, the round body forms were more susceptible to the
tested drugs or drug combinations than the 10 day old stationary
phase culture which was enriched with more resistant aggregated
microcolonies (Feng et al., 2014a, 2015) (Table 2). It is worth
noting that antimalarial drug artemisinin highlighted itself as
having among the best activity against the stationary phase
B. burgdorferi persisters when combined with other drugs.
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FIGURE 3 | Representative images (400 × magnification) of amoxicillin-induced round body form of B. burgdorferi treated with different antibiotics
(labeled on the image). A 6- day old culture was induced with 50 µg/ml amoxicillin for 72 h and subsequently treated with the listed antibiotics (50 µM) for 7 days
followed by staining with SYBR Green I/PI assay and fluorescence microscopy.
For example, artemisinin in combination with doxycycline and
cefoperazone showed excellent activity against the stationary
phase B. burgdorferi persisters (24% residual viable cells, Table 2,
Figure 4, o). Cefmenoxime and cefmetazole were the most
effective of the cephalosporin drugs tested against the round
body form of B. burgdorferi. In addition, we noted that the
TABLE 2 | Effect of drug combinations on the round body form and
stationary phase culture of B. burgdorferi persisters∗
Live cell % CefM Scp Art Nft
Control 50% (87%) 34% (53%) 38% (68%) 28% (73%) 33% (82%)
Dox 49% (72%) 31% (43%) 29% (62%) 26% (64%) 30% (74%)
CefP 30% (64%) 31% (41%) 30% (55%) 25% (42%) 25% (56%)
Dox + CefP 29% (59%) 28% (41%)† 25% (69%) 23% (24%)‡ 23% (52%)
DAP 17% (48%) 16% (20%) 15% (27%) 24% (29%) 16% (33%)
DAP + Dox 16% (34%) 16% (16%) 8% (21%) 15% (19%) 17% (20%)
∗Round body form and 10-day old stationary phase culture (values in brackets) of
B. burgdorferi was treated with 10 µg/ml drugs or their combinations for 7 days.
Residual viable B. burgdorferi was calculated according to the regression equation
and ratio of Green/Red fluorescence obtained by SYBR Green I/PI assay as
described (Feng et al., 2014a). Direct microscopy counting was employed to rectify
the results of the SYBR Green I/PI assay. †The best drug combinations without
daptomycin are underlined. ‡Residual viable percentages less than 30% are shown
in bold type. Abbreviation: Dox, doxycycline; CefP, cefoperazone; DAP, daptomycin;
CefM, cefmetazole; Scp, sulfachlorpyridazine; Art, artemisinin; Nft, nitrofurantoin.
sulfa drug sulfachlorpyridazine when combined with daptomycin
and doxycycline showed good activity against B. burgdorferi
persisters (21% residual viable cells, Figure 4, n). Moreover,
sulfachlorpyridazole combined with doxycycline and daptomycin
showed the best activity against the round body form of
B. burgdorferi persisters (8% residual cells, Table 2).
We also tested some drugs and drug combinations on a
different clinical isolate B. burgdorferi strain 297 to confirm if they
also work on different strains other than strain B31. Indeed, we
found no significant difference in the activity of these drugs and
drug combinations for the two different strains (Figure 4B).
Subculture Studies to Evaluate the
Activity of Drug Combinations against
Round Bodies
To confirm the durability of the drug combinations in killing
round bodies, we performed subculture studies in BSK-H
medium as described in our previous study (Feng et al.,
2015). We found that drug-free round body controls and
samples treated with any single drugs grew back routinely in
10-day subcultures (Table 3). Samples treated with two drug
combinations grew more slowly (Table 3). However, the three
drug combinations, e.g., doxycycline/daptomycin plus either
cefoperozone or artemisinin or sulfachlorpyridazine did not
show any sign of growth as no visible spirochetes were observed
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FIGURE 4 | Effect of antibiotics alone or in combinations on stationary phase B. burgdorferi strain B31 (A) and strain 297 (B) microcolonies. Stationary
phase culture of B. burgdorferi (10-day old) was treated with 10 µg/ml drugs alone or in combinations (labeled on the image) for 7 days followed by staining with
SYBR Green I/PI assay and epifluorescence microscopy (200 × magnification). Green cells indicate live cells whereas red cells dead cells. Abbreviation: Dox,
doxycycline; CefP, cefoperazone; Art, Artemisinin; Dap, daptomycin; CefM, cefmetazole; Scp, sulfachlorpyridazine.
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TABLE 3 | Subculture following exposure to single drugs or drug
combinations to assess the viability of remaining round body forms of
B. burgdorferi.∗
Drugs† Residual
viable cells‡
Spirochetes number
after 10 days
subculture§
Spirochetes number
after 20 days
subculture§
Control 49% 2 × 106 8 × 106
Dox 44% 1 × 106 5 × 106
Dox + Dap + CefP 13% <1 × 105 <1 × 105¶
Dox + Dap + Art 15% <1 × 105 3 × 105
Dox + Dap + Scp 17% <1 × 105 6 × 105
Dox + CefP 31% 7.5 × 105 4 × 106
Dap 18% 5 × 105 5 × 106
CefP 33% 9 × 105 4 × 106
∗Amoxicillin induced round body form B. burgdorferi culture (500 µl) was treated
with 10 µg/ml drugs alone or drug combinations for 7 days. Then, 50 µl of washed
bacterial cells was subcultured in 1 ml fresh BSK-H medium for 10 and 20 days,
respectively and examined by microscopy. †Abbreviations: Dox, doxycycline;
CefP, cefoperazone; Dap, daptomycin; Art, artemisinin; Scp, sulfachlorpyridazine.
‡Green/Red fluorescence ratios were obtained by microplate reader after SYBR
Green I/PI staining. Each value is the mean of three replicates. §The number of
spirochetes was evaluated by microscope count. ¶Below the detection limit as
shown by lack of any visible spirochetes by microscopy.
after 10-day subculture, whereas other drug combinations
all had visible live spirochetes growing as observed by SYBR
Green I/PI microscopy (Table 3). After 20-day subculture,
there were about 8 × 106 spirochetes in the control sample
and about 5 × 106 spirochetes in doxycycline-treated samples
(Table 3). Daptomycin alone, or two drug combinations
doxycycline/cefoperazone and doxycycline/daptomycin could
not sterilize the round bodies of burgdorferi, as they all had
visible spirochetes growing after 20 day subculture (Figure 5).
However, doxycycline/daptomycin and either artemisinin
or sulfachlorpyridazine significantly reduced the number of
spirochetes with very few spirochetes being visible after 20 day
subculture (Figure 5). As in our previous study (Feng et al., 2015),
daptomycin in combination with doxycycline and cefoperazone
also showed the best activity which killed all round body form
of B. burgdorferi persisters with no viable spirochetes observed
after 20 day subculture (Figure 5). In a separate experiment, we
found BSK-H medium stored under experimental conditions
for 20 days showed no loss or inactivation of nutrients, since
B. burgdorferi displayed the same normal exponential growth in
either 20 day old medium or fresh medium.
DISCUSSION
Previous in vitro studies showed that the round body form
of B. burgdorferi as a persister form could survive in
adverse conditions including antibiotic exposure in culture
(Kersten et al., 1995; Brorson et al., 2009; Barthold et al.,
2010). Although metronidazole, tinidazole and tigecycline were
reported individually to have activity against these round body
forms, they were unable to completely eradicate these persisters
in culture (Sapi et al., 2011). In this study, to identify more
effective drugs active against round bodies, we first established
an amoxicillin-induced round body model of B. burgdorferi
persisters and then screened an FDA-approved drug library for
highest activities against the round bodies. We were able to
identify 23 drug candidates that are more active than doxycycline
or amoxicillin, 11 of which had better activity against the round
body form of B. burgdorferi (Table 1) than metronidazole or
tinidazole, which were previously cited as having such abilities
to kill round body forms (Brorson and Brorson, 1999; Sapi et al.,
2011).
We used a relatively high concentration (50 µM) of drug
candidates in the drug screen. A major reason to do so is
that lower concentration of drugs (10 µM commonly used
in different drug screens) in our previous studies identified
very few drug candidates because stationary phase cultures or
round body forms induced by amoxicillin are quite resistant to
drugs or antibiotics. This necessitates the use of higher drug
concentrations to identify any drug candidates with activity
against these resistant forms. Some of the identified drug
candidates though show weak activity on their own, can be quite
active in the drug combinations (Feng et al., 2015, 2016). Thus,
an initial relatively high drug concentration would be helpful to
identify these drugs in the high throughput screen, and this is
followed by use of a lower concentration (10 µg/ml) for each
candidate drug in drug combination tests which show good
activity. It is worth noting that most drugs’ Cmax values are
higher than or close to this 10 µg/ml concentration used in this
study.
In a previous study, we identified several drugs that show
excellent activity against stationary phase B. burgdorferi from
an FDA drug library (Feng et al., 2014a). Replication of activity
against B. burgdorferi round body persisters by daptomycin,
clofazimine and sulfa drugs in this study validates our previous
findings that such drugs are active against persisters in the
stationary phase model (Feng et al., 2014a). Importantly, we
also identified additional drugs active against the amoxicillin-
induced round bodies of B. burgdorferi that did not show good
activity in the previous drug screen against the stationary phase
B. burgdorferi (Feng et al., 2014a). These include artemisinin,
ciprofloxacin, nifuroxime, fosfomycin, tinidazole, loracarbef, and
thymol that appear to have enhanced activity against the round
body form. The reason why these new drug candidates are
identified that are distinct from the previous screen on stationary
phase culture without antibiotic treatment is presumably a
reflection of the difference in the amoxicillin-induced round
bodies being used in this screening process. Nevertheless, it is
interesting that despite the difference of the two models, some
common drug candidates such as daptomycin, clofazimine and
sulfa drugs were found to be active in both persister models.
These findings suggest the two persister models, i.e., stationary
phase culture and amoxicillin-treated, may have overlapping
persister cell subpopulation characteristics among the very
heterogeneous persister population (Feng et al., 2014a; Zhang,
2014). Both may be useful methods for persister drug screenings.
As in our previous study (Feng et al., 2014a), daptomycin
remains the most active drug against the round bodies of
B. burgdorferi. Daptomycin killed most planktonic round body
form of B. burgdorferi (Figure 3b). It is possible that daptomycin
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FIGURE 5 | Subculture of amoxicillin-induced round bodies of B. burgdorferi after treatment with different antibiotics alone or in combinations
(labeled on the image). Six day old of B. burgdorferi culture was induced with 50 µg/ml amoxicillin for 72 h to form round bodies, which were then treated with
single antibiotics alone or in combination. Representative images (200 × magnification) were taken with fluorescence microscopy using SYBR Green I/PI staining.
Only Dox + Dap + CefP completely killed all round body B. burgdorferi persisters as shown by lack of any viable green spirochetes after 20-day subculture.
Abbreviation: Dox, doxycycline; CefP, cefoperazone; Dap, daptomycin; Art: artemisinin; Scp, sulfachlorpyridazine.
preferentially acts on the membrane of the round body form of
B. burgdorferi that is different from the membrane of actively
growing spirochetal form. Daptomycin is known to disrupt
the Staphylococcus aureus membrane structure and cause rapid
depolarization thus depleting membrane energy that may be
required for viability of the persisters (Pogliano et al., 2012). The
drug has been shown to work more effectively in combination
with beta-lactams, for example, against antibiotic resistant
enterococci (Brown et al., 2015).
An interesting finding of the study is the observation
that the antimalarial drug artemisinin also showed excellent
activity against the round body form of B. burgdorferi persisters
(Figure 3e). It is worth noting that artemisinin similar to
daptomycin has a high MIC (50–100 µg/ml) against growing
B. burgdorferi, while showing excellent activity against the
round bodies of B. burgdorferi. Artemisinin is a commonly
used antimalarial drug isolated from the wormwood plant
Artemisia annua, a Chinese herbal medicine. The mechanism
of artemisinin action is not well understood. The antimalarial
activity of artemisinin might involve endoperoxide activation
by free ferrous iron from hemoglobin digestion by malaria
parasites (Wells et al., 2009). However, the content of ferrous
iron or hemoglobin is very low in the B. burgdorferi culture
(Rodriguez et al., 2007), so the activation of endoperoxide
might not be the main mechanism of artemisinin activity
against B. burgdorferi round bodies. In yeast, artemisinin impairs
the membrane structure and causes depolarization of the
mitochondrial membrane (Li et al., 2005; Wang et al., 2010). In
this respect, it is possible that artemisinin may have a similar
mechanism of action as daptomycin in disrupting the bacterial
membrane as the basis for its high activity against the round
bodies of B. burgdorferi.
We previously found daptomycin combined with doxycycline
and cefoperazone could best eliminate the most resistant biofilm-
like microcolonies of B. burgdorferi (Feng et al., 2015, 2016). In
this study, we found artemisinin was the best alternative drug
in combination with doxycycline and cefoperazone compared to
daptomycin-containing regimen and showed excellent activity
against the amoxicillin-induced round body form of persisters
(Table 2; Figure 3c). We also noticed the lipophilic antibiotic
Frontiers in Microbiology | www.frontiersin.org 9 May 2016 | Volume 7 | Article 743
fmicb-07-00743 May 20, 2016 Time: 19:28 # 10
Feng et al. FDA-Drugs against Borrelia Round Bodies
clofazimine, which has complex antimicrobial activity including
membrane disruption and depolarization (Van Rensburg et al.,
1992; Cholo et al., 2012), also showed good activity against
both round body form and stationary phase persisters (Feng
et al., 2014a). The results using artemisinin, clofazimine and
daptomycin (Feng et al., 2014a) suggest membrane disruption
may be a good approach to killing B. burgdorferi persisters.
Besides the top-ranked hits of screened drugs, we
found many sulfonamide antibiotics such as sulfacetamide,
sulfamethoxypyridazine and sulfaquinoxaline are highly active
against the round body form (Table 1). The sulfonamide
antibiotics have also been identified in the previous drug screen
against stationary phase persisters and showed low MICs
(<0.2 µg/ml) (Feng et al., 2014a). The sulfonamides inhibit
utilization of PABA required for the synthesis of folic acid, which
results in blockade of several enzymes needed for synthesis of
DNA and methionine, glycine, and formylmethionyl-transfer-
RNA. Because methionine is a methyl group donor, sulfa
drugs may also inhibit methylation process in B. burgdorferi,
which may be important for their anti-persister activity. It
is worth noting that sulfachloropyridazine as an analog of
sulfamethoxypyridazine also showed good activity against
stationary phase B. burgdorferi (residual viable cells about 38%).
When combined with daptomycin/doxycycline this trio showed
remarkable activity against stationary phase B. burgdorferi
(residual viable cells is about 8%) (Table 2). We believe that
further studies on metabolic changes of the round body form of
B. burgdorferi could help understand the mechanisms by which
sulfa drugs act against B. burgdorferi persisters.
In addition to the previously described daptomycin,
clofazimine, cefoperazone and, sulfa drugs (Feng et al., 2014a),
we also discovered some additional drugs preferentially active
against the amoxicillin-induced round bodies of B. burgdorferi.
The fluoroquinolone drug ciprofloxacin has previously been
shown to be active against B. burgdorferi in vitro and could kill
the inoculum at a relatively high concentration of 16 µg/ml
minimum bactericidal concentration (MBC) (41.5 µM) after
72 h incubation (Kraiczy et al., 2001). Here we found that
ciprofloxacin was the most active of the fluoroquinolones against
the round bodies of B. burgdorferi, but it was not identified to
have activity against B. burgdorferi stationary phase persisters
in our previous screen (Feng et al., 2014a) as it was not in the
prior version of the FDA drug library (version 1.1). However,
ciprofloxacin (50 µM) alone could not completely kill the round
bodies after 7 days. This indicates that the round body form
is more resistant or tolerant to this antibiotic than multiplying
B. burgdorferi. On the other hand, we also noticed some drugs
such as nifuroxime and thymol did not show activity in the
previous drug screens on stationary phase B. burgdorferi (Feng
et al., 2014a, 2015), but showed good activity against the round
body form in this study. This specific activity against the round
body form could be related to the physiological difference of
different morphological forms and/or the synergistic activity
of these drugs with amoxicillin used to induce round forms
used for drug screens. It is of interest that chlortetracycline was
more active than doxycycline against the round body forms
and that nitrofuran derivative nifuroxime was more active than
metronidazole or tinidazole (Table 1). These findings could
indicate the side chain involved in both cases may have conferred
additional activity against the round body persisters.
We did the drug combination test on the stationary phase
B. burgdorferi using the nifuroxime analog nitrofurantoin
(residual live cell, 39%), and the results showed that
nitrofurantoin combined with cefoperazone was more
effective than each drug alone (Table 2). Likewise, the natural
antimicrobial thymol combined with amoxicillin showed good
activity (residual percentage, 34%) in the round body drug
screen but thymol alone did not work on the stationary phase
B. burgdorferi (residual live cell percentage, 82%) in the previous
drug screen. Palaniappan and Holley (2010) reported that thymol
could reduce the resistance in E. coli and S. aureus to ampicillin
and penicillin. This synergistic activity between thymol and beta-
lactams may explain its activity against the B. burgdorferi round
body form. These results suggest that the drug combination
could be an effective approach if B. burgdorferi persisters are
playing a significant role.
However, some drugs that had activity against stationary phase
B. burgdorferi such as beta-lactams, vancomycin, streptomycin,
and amphotericin B (Feng et al., 2014a) did not show good
activity against the round body form (Table 1). However, we
noted two cephalosporins, cefmenoxime and cefmetazole showed
good activity against the round body form of B. burgdorferi.
In the previous drug screen on stationary phase B. burgdorferi,
cefoperazone, which was the best cephalosporin for killing
stationary phase B. burgdorferi, also had certain activity against
the round body form (not shown). Future studies are needed to
explore the mechanism of action of these cephalosporins that
have activity against the round body B. burgdorferi persisters
which may involve targets beyond the cell wall synthesis.
Vancomycin is a glycopeptide antibiotic acting on the cell wall
rather than acting on the cell membrane like daptomycin. We did
not find good activity of vancomycin against amoxicillin treated
round bodies, though it showed relatively good activity against
stationary phase B. burgdorferi in the previous drug screen (Feng
et al., 2014a). This might be due to the relative cell wall deficiency
state of the round body form induced by amoxicillin.
Despite the description of drug candidate’s active against the
round body forms, their significance in improving the treatment
remains to be determined. While evidence that round body
form of persisters examined in this study may occur in vivo
during infection remains to be confirmed, it is also unknown
if antibiotics that target such potential persisters would lead to
improved outcomes in human infection compared with standard
Lyme disease treatment with doxycycline or amoxicillin that
do not have good activity against the round body forms of
B. burgdorferi (Brorson et al., 2009; Barthold et al., 2010) or if
they even induce such forms in vivo. These studies indicate that it
would be difficult to kill the round body form of B. burgdorferi
using the current Lyme antibiotics if similar organisms exist
in vivo or are incompletely eradicated in the human host under
environmental stressors. The drug candidates identified in this
study could allow the above possibility to be tested in animal
models of persistence using the drug combinations that are active
against round body forms of B. burgdorferi in the future.
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In summary, this study represents the first high
throughput drug combination screen using an FDA
library against amoxicillin-induced round body forms
of B. burgdorferi. Several FDA-approved drugs show
excellent activity against such forms. Drug candidates
that are preferentially active against the round bodies
include artemisinin, ciprofloxacin, nifuroxime, fosfomycin,
chlortetracycline, and some sulfa drugs. We found that
triple drug combinations artemisinin/cefoperazone/doxycycline,
daptomycin/sulfachlorpyridazine//doxycycline and daptomycin
/cefoperazone/ doxycycline had among the best activity against
both the round body model and the stationary phase persister
model. These round body effective drugs and drug combinations
provide new candidates for further evaluation in animal studies
and potentially clinical investigation to determine whether drug
combinations could improve resolution of symptoms in those
patients who do not appropriately or completely respond to
traditional antibiotic therapy for Lyme disease.
CONCLUSION
In this study, we performed a drug combination screen using
an FDA drug library on amoxicillin-induced round bodies of
B. burgdorferi that identified 23 drug candidates with higher
activity than either amoxicillin or doxycycline. Eleven of the
23 candidates had higher anti-round body activity than either
metronidazole or tinidazole. Although some drug candidates
such as daptomycin and clofazimine overlapped with a previous
screen against stationary phase B. burgdorferi, new active
drug candidates identified include artemisinin, ciprofloxacin,
nifuroxime, fosfomycin, chlortetracycline, sulfacetamide,
sulfamethoxypyridazine and sulfathiozole that have high
activity against round body forms. We found two triple
drug combinations artemisinin/cefoperazone/doxycycline and
sulfachlorpyridazine/daptomycin/doxycycline, which had the
highest activity against round bodies and stationary phase
B. burgdorferi persisters. Further in vivo animal and human
studies are needed to evaluate the significance of these findings
for improved treatment of Lyme disease.
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